# Namodenoson Treatment of Advanced Pancreatic Cancer

> **NCT06387342** · PHASE2 · RECRUITING · sponsor: **Can-Fite BioPharma** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** Namodenoson 25mg

## Key facts

- **NCT ID:** NCT06387342
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-10
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06387342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06387342, "Namodenoson Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06387342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*